Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses.
Aged
Biomarkers, Tumor
/ blood
Case-Control Studies
Colorectal Neoplasms
/ blood
Female
Follow-Up Studies
Humans
Incidence
Insulin-Like Growth Factor Binding Protein 3
/ blood
Insulin-Like Growth Factor I
/ analysis
Insulin-Like Growth Factor II
/ analysis
Male
Mendelian Randomization Analysis
Middle Aged
Polymorphism, Single Nucleotide
Registries
/ statistics & numerical data
Risk Assessment
/ methods
Risk Factors
Sex Factors
United Kingdom
/ epidemiology
CRC
GWAS
Risk Factors
Signal Transduction
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
05
09
2019
revised:
13
12
2019
accepted:
19
12
2019
pubmed:
31
12
2019
medline:
11
7
2020
entrez:
30
12
2019
Statut:
ppublish
Résumé
Human studies examining associations between circulating levels of insulin-like growth factor 1 (IGF1) and insulin-like growth factor binding protein 3 (IGFBP3) and colorectal cancer risk have reported inconsistent results. We conducted complementary serologic and Mendelian randomization (MR) analyses to determine whether alterations in circulating levels of IGF1 or IGFBP3 are associated with colorectal cancer development. Serum levels of IGF1 were measured in blood samples collected from 397,380 participants from the UK Biobank, from 2006 through 2010. Incident cancer cases and cancer cases recorded first in death certificates were identified through linkage to national cancer and death registries. Complete follow-up was available through March 31, 2016. For the MR analyses, we identified genetic variants associated with circulating levels of IGF1 and IGFBP3. The association of these genetic variants with colorectal cancer was examined with 2-sample MR methods using genome-wide association study consortia data (52,865 cases with colorectal cancer and 46,287 individuals without [controls]) RESULTS: After a median follow-up period of 7.1 years, 2665 cases of colorectal cancer were recorded. In a multivariable-adjusted model, circulating level of IGF1 associated with colorectal cancer risk (hazard ratio per 1 standard deviation increment of IGF1, 1.11; 95% confidence interval [CI] 1.05-1.17). Similar associations were found by sex, follow-up time, and tumor subsite. In the MR analyses, a 1 standard deviation increment in IGF1 level, predicted based on genetic factors, was associated with a higher risk of colorectal cancer risk (odds ratio 1.08; 95% CI 1.03-1.12; P = 3.3 × 10 In an analysis of blood samples from almost 400,000 participants in the UK Biobank, we found an association between circulating level of IGF1 and colorectal cancer. Using genetic data from 52,865 cases with colorectal cancer and 46,287 controls, a higher level of IGF1, determined by genetic factors, was associated with colorectal cancer. Further studies are needed to determine how this signaling pathway might contribute to colorectal carcinogenesis.
Sections du résumé
BACKGROUND & AIMS
Human studies examining associations between circulating levels of insulin-like growth factor 1 (IGF1) and insulin-like growth factor binding protein 3 (IGFBP3) and colorectal cancer risk have reported inconsistent results. We conducted complementary serologic and Mendelian randomization (MR) analyses to determine whether alterations in circulating levels of IGF1 or IGFBP3 are associated with colorectal cancer development.
METHODS
Serum levels of IGF1 were measured in blood samples collected from 397,380 participants from the UK Biobank, from 2006 through 2010. Incident cancer cases and cancer cases recorded first in death certificates were identified through linkage to national cancer and death registries. Complete follow-up was available through March 31, 2016. For the MR analyses, we identified genetic variants associated with circulating levels of IGF1 and IGFBP3. The association of these genetic variants with colorectal cancer was examined with 2-sample MR methods using genome-wide association study consortia data (52,865 cases with colorectal cancer and 46,287 individuals without [controls]) RESULTS: After a median follow-up period of 7.1 years, 2665 cases of colorectal cancer were recorded. In a multivariable-adjusted model, circulating level of IGF1 associated with colorectal cancer risk (hazard ratio per 1 standard deviation increment of IGF1, 1.11; 95% confidence interval [CI] 1.05-1.17). Similar associations were found by sex, follow-up time, and tumor subsite. In the MR analyses, a 1 standard deviation increment in IGF1 level, predicted based on genetic factors, was associated with a higher risk of colorectal cancer risk (odds ratio 1.08; 95% CI 1.03-1.12; P = 3.3 × 10
CONCLUSIONS
In an analysis of blood samples from almost 400,000 participants in the UK Biobank, we found an association between circulating level of IGF1 and colorectal cancer. Using genetic data from 52,865 cases with colorectal cancer and 46,287 controls, a higher level of IGF1, determined by genetic factors, was associated with colorectal cancer. Further studies are needed to determine how this signaling pathway might contribute to colorectal carcinogenesis.
Identifiants
pubmed: 31884074
pii: S0016-5085(19)41951-3
doi: 10.1053/j.gastro.2019.12.020
pmc: PMC7152801
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
IGF1 protein, human
0
IGF2 protein, human
0
IGFBP3 protein, human
0
Insulin-Like Growth Factor Binding Protein 3
0
Insulin-Like Growth Factor I
67763-96-6
Insulin-Like Growth Factor II
67763-97-7
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1300-1312.e20Subventions
Organisme : NCI NIH HHS
ID : R01 CA059045
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA097735
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074799
Pays : United States
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : K05 CA154337
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA201407
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA196569
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR000421
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100001C
Pays : United States
Organisme : Medical Research Council
ID : MC_PC_12028
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U24 CA074800
Pays : United States
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 10589
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Organisme : Cancer Research UK
ID : C8221/A19170
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA137178
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074783
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074806
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA037429
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA190673
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074794
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK034987
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U01 CA137088
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA076366
Pays : United States
Organisme : Cancer Research UK
ID : 19167
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U19 CA148107
Pays : United States
Organisme : NIEHS NIH HHS
ID : T32 ES013678
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189974
Pays : United States
Organisme : NIA NIH HHS
ID : HHSN271201100004C
Pays : United States
Organisme : Department of Health
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA207371
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA151993
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA189184
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA127003
Pays : United States
Organisme : Cancer Research UK
ID : C490/A16561
Pays : United Kingdom
Organisme : Medical Research Council
ID : 1000143
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U01 CA167551
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201500005C
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197735
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100004C
Pays : United States
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C570/A16491
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : UM1 CA182883
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA122839
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167552
Pays : United States
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C588/A19167
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U01 CA074800
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201100046C
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100003C
Pays : United States
Organisme : Cancer Research UK
ID : 25004
Pays : United Kingdom
Organisme : NCATS NIH HHS
ID : KL2 TR002317
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA042182
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074794
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074806
Pays : United States
Organisme : Medical Research Council
ID : MR/L01629X/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA136726
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA206110
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100002C
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA055075
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA097735
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074799
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA153323
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA097325
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201200008I
Pays : United States
Organisme : NCI NIH HHS
ID : K05 CA152715
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197350
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA063464
Pays : United States
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P01 CA033619
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074783
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Informations de copyright
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Genet Epidemiol. 2013 Nov;37(7):658-65
pubmed: 24114802
Int J Endocrinol. 2010;2010:
pubmed: 20885914
J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600
pubmed: 11018095
J Biol Chem. 1995 Jun 9;270(23):13589-92
pubmed: 7539790
Int J Cancer. 2019 Sep 1;145(5):1238-1244
pubmed: 31131883
Lancet. 1990 Mar 31;335(8692):765-74
pubmed: 1969518
Br J Cancer. 2006 Jul 3;95(1):112-7
pubmed: 16804529
J Bone Miner Res. 2011 Sep;26(9):2298-306
pubmed: 21590739
Front Oncol. 2018 Apr 16;8:103
pubmed: 29713614
Oncogene. 2017 Sep 21;36(38):5341-5355
pubmed: 28534511
Genet Epidemiol. 2016 May;40(4):304-14
pubmed: 27061298
Cancer Res. 2008 Jan 1;68(1):329-37
pubmed: 18172327
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):850-5
pubmed: 15824155
Nat Genet. 2021 Feb;53(2):185-194
pubmed: 33462484
J Natl Cancer Inst. 1999 Apr 7;91(7):620-5
pubmed: 10203281
Endocr Rev. 2007 Feb;28(1):20-47
pubmed: 16931767
Nat Rev Cancer. 2008 Dec;8(12):915-28
pubmed: 19029956
Eur J Epidemiol. 2015 Jul;30(7):543-52
pubmed: 25773750
Gastroenterology. 2004 Apr;126(4):964-70
pubmed: 15057734
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3108-15
pubmed: 18990751
Int J Epidemiol. 2013 Oct;42(5):1497-501
pubmed: 24159078
Mol Pathol. 2001 Jun;54(3):145-8
pubmed: 11376125
Bioinformatics. 2019 Nov 1;35(22):4851-4853
pubmed: 31233103
Int J Cancer. 2003 Oct 20;107(1):89-93
pubmed: 12925961
Eur Heart J. 2008 Mar;29(6):800-9
pubmed: 18303034
Science. 2003 Mar 14;299(5613):1753-5
pubmed: 12637750
Int J Epidemiol. 2015 Apr;44(2):512-25
pubmed: 26050253
Nat Genet. 2018 May;50(5):693-698
pubmed: 29686387
J Natl Cancer Inst. 2015 Aug 01;107(10):
pubmed: 26232761
Int J Cancer. 1994 Aug 1;58(3):452-9
pubmed: 8050827
Cancer Res. 2003 Nov 15;63(22):7708-16
pubmed: 14633695
Hum Mol Genet. 2014 Sep 15;23(R1):R89-98
pubmed: 25064373
Mol Pathol. 2001 Jun;54(3):133-7
pubmed: 11376123
Br J Cancer. 2001 Nov 30;85(11):1695-9
pubmed: 11742490
J Clin Endocrinol Metab. 2001 Mar;86(3):1274-80
pubmed: 11238520
Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):345-9
pubmed: 10794477
Front Oncol. 2015 Oct 15;5:230
pubmed: 26528439
Aging Cell. 2016 Oct;15(5):811-24
pubmed: 27329260
Am J Epidemiol. 2010 Aug 15;172(4):407-18
pubmed: 20634278
Growth Horm IGF Res. 2015 Apr;25(2):90-5
pubmed: 25641638
Nat Genet. 2019 Jan;51(1):76-87
pubmed: 30510241
Int J Cancer. 2007 May 1;120(9):2007-12
pubmed: 17266031
Cell Metab. 2014 Mar 4;19(3):407-17
pubmed: 24606898
Am J Epidemiol. 1999 Aug 15;150(4):341-53
pubmed: 10453810
Cancer Causes Control. 2012 Jun;23(6):907-17
pubmed: 22527168
Int J Cancer. 2010 Apr 1;126(7):1702-15
pubmed: 19810099
Int J Biochem Cell Biol. 1996 Jun;28(6):619-37
pubmed: 8673727